LinkedIn · Jul 2026
Company post noting workshop sponsorship and that co-founder/CSO Ashwin Jainarayanan presented the work, with co-founder Michael Dustin thanked as an organizer.
Reprogramming Immunity for Target-Specific Medicines
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Granza Bio is a San Francisco-based biotechnology startup building programmable therapeutic delivery shells around immune-system “attack particles” (supramolecular attack particles/SMAPs) for cancer and other hard-to-treat diseases. Public company materials and press describe the company as founded in 2024, though LinkedIn also lists 2023.
Primary product
Precision delivery shell platform for immune “attack particles” / therapeutic cargo delivery
Founded
2024
Headquarters
San Francisco, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Drug discovery / oncology therapeutics
Offices
Open Positions
0 jobs at Granza Bio
No open positions
Check back later for new openings